Trial watch: IDO inhibitors in cancer therapy

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first, rate-limiting step of the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan (Trp) into the immunosuppressive metabolite L-kynurenine (Kyn). While expressed constitutively by some tissues, IDO1 can also be in...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Naour, Julie, Galluzzi, Lorenzo, Zitvogel, Laurence, Kroemer, Guido, Vacchelli, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466863/
https://www.ncbi.nlm.nih.gov/pubmed/32934882
http://dx.doi.org/10.1080/2162402X.2020.1777625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466863/
https://www.ncbi.nlm.nih.gov/pubmed/32934882
http://dx.doi.org/10.1080/2162402X.2020.1777625

Ejemplares similares